Join us for our Third Annual Life Sciences Forum Presented by ICON plc, sponsored by Aer Lingus Innovation and the Financial Impact Along the Drug Development Path
Innovation often starts the drug discovery process, but innovation also inspires change in development, manufacturing, supply chain, and drug delivery in nearly every step of the drug development continuum. The financial impact can also be seen at all levels of development. The debate over rising drug prices has become a full-blown blaming game with drug companies pointing the finger at middlemen in the health-care system, saying they not only benefit from rising drug prices but contribute to their increases…Who is responsible for high drug pricing? The Irish Chamber’s third annual Life Sciences Forum brings a unique and deep perspective to this debate.
Location Offices of ICON Clinical Research 2100 Pennbrook Parkway North Wales, PA 19454, USA
Key Note Speaker: Dr. Garret FitzGerald, MD, FRS Director, Institute for Translational Medicine & Therapeutics, University of Pennsylvania
Dr. Andrea Perrone, MD Associate Vice President, Clinical Imaging Translational Medicine, Merck & Co
Mr. Joseph Sirianni Senior Director Global Engineering Services, Zoetis
Moderator: Paul McCracken Ph.D. Vice President, Head of Medical Imaging, ICON plc.
1.00 pm: Registration & Networking 1.30 pm: Welcoming Remarks 1.35 pm: Introduction of Speakers 1.45 pm: Key Note Presentation 2.15 pm: Panel Discussion and Question & Answer Session 3.30 pm: Conclusion/Closing Remarks 3:30 – 5.30pm: Networking Reception
Directions & Parking
For directions, please click HERE. Complimentary parking is available on site.
Members – $50.00
— Non-Members – $65.00
*ICON employees: please click HERE to register. ~ Companies Represented at this event:
|McLaughlin & Morgan
|Conrad O’Brien PC
|Modern Strategic Branding + Communications
|Newmark Knight Frank
|OPS Security Group
|Pepper Hamilton LLP
|Hanna Moore + Curley
|PMB Marketing LLC
|PNC Wealth Management
|HPT Pharma, LLC
|Post & Schell, P.C.
|ICON Clinical Research
|Sterling Investment Advisors
|Innovative Development LLC
|The Graham Company
|Javan Engineering, Inc.
|The Safeguard Group
|University of Pennsylvania
|KBC Financial Services, Inc.
|Volpe and Koenig
~ Please register by Monday, November 13th. All reservations binding unless cancelled by Monday, November 13th. ~ Questions? Please contact Alanna Barry McCloskey at email@example.com or call/text 215.772.3101. ~~~ About Our Speakers * Dr. Garret A. FitzGerald, MD, FRS is the McNeil Professor in Translational Medicine and Therapeutics at the University of Pennsylvania in Philadelphia, where he chairs the Department of Systems Pharmacology and Translational Therapeutics and directs the Institute for Translational Medicine and Therapeutics. Dr. FitzGerald’s research has been characterized by an integrative approach to elucidating the mechanisms of drug action, drawing on work in cells, model organisms and humans. His work contributed fundamentally to the development of low-dose aspirin for cardioprotection. FitzGerald’s group was the first to predict and then mechanistically explain the cardiovascular hazard from NSAIDs. He has also discovered many products of lipid peroxidation and established their utility as indices of oxidant stress in vivo. His laboratory was the first to discover a molecular clock in the cardiovascular system and has studied the importance of peripheral clocks in the regulation of cardiovascular and metabolic function. Dr. FitzGerald has received the Boyle, Coakley, Harvey and St. Patrick’s Day medals, the Lucian, Scheele and Hunter Awards, the Presidential Award for the Irish Abroad and the Cameron, Taylor, Herz, Lefoulon-Delalande, and Schottenstein Prizes. He is a member of the National Academy of Medicine, an honorary member of the Royal Irish Academy and a Fellow of the American Academy of the Arts and Sciences and of the Royal Society. * Dr. Andrea Perrone, MD joined Merck 5 years ago and is currently the Associate Vice President of Clinical Imaging in Translational Medicine. She and her team provide imaging expertise in protocol development, execution and regulatory support for clinical trials of therapeutic agents across all disease indications. Prior to joining Merck, Dr Perrone was the Head of Late Clinical Development at GE Healthcare contributing to new ultrasound, CT and PET imaging agents. Other roles include VP, Clinical Operations and Medical Director at BioClinica as well as Director, Clinical Development at a biomarker discovery start-up, SurroMed that was subsequently acquired by PPD. She obtained a BS in Finance from the University of Maryland and then transitioned into the sciences. Dr Perrone completed medical school and an internship at Georgetown University Medical School as well as a radiology residency at the University of Pittsburgh. * Mr. Joseph Sirianni is currently the Senior Director Global Engineering at Zoetis. He was responsible for the design of the global function and instrumental in the evaluation of the Pfizer Animal Health Engineering Organization, development of the Engineering support model for Zoetis including the separation of manufacturing operations from Pfizer. At Zoetis he leads a group of technical experts that guide the execution of capital investments, bring technologies to manufacturing for new products and enabling efficient manufacturing processes. Prior to the stand-up of Zoetis Joe was a technical leader in the Pfizer global engineering group responsible for supporting a number of manufacturing sites in technical areas including, capital execution, maintenance reliability and process/ packaging technologies for pharm and biologics operations. Prior to Pfizer he lead the design and Pharmaceutical engineering functions for several Architectural and Engineering Firms including AMEC and bioKinetics. Joe has a BSME from Boston University. * Dr. Paul McCracken has over 20 years’ experience in imaging and pharmaceuticals, with a strong track record of applying imaging and biomarkers to drug discovery and development across a range of therapeutic areas. Dr. McCracken joined ICON from Eisai, where he led the Imaging Centre of Excellence, which drives novel approaches for discovery targets and translational biomarkers, primarily through the introduction of imaging genetics and the acceleration of novel PET approaches. Prior to Eisai, Paul worked at Merck Research Laboratories, where he developed preclinical and translational imaging biomarkers and strategies to assess new molecular and biologic entities. Dr. McCracken holds a Bachelor of Science in Physics from The College of New Jersey, a Master of Science in Physics/Medical Physics from Wright State University and received his Ph.D. in Biomedical Engineering – Imaging from the Mayo Clinic College of Medicine ~~~ *Please note our Attendee Policy* Irish Chamber programs are privately sponsored events with a structured format. No demonstrations or other disruptions will be tolerated. Violation of this policy may result in the attendee’s removal from the premises without refund, in addition to possible legal remedies.